Form 6-K Controladora Vuela Compa For: Jun 30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934
For the month of April 2026
Commission File Number: 001-36059
Controladora Vuela Compañía de Aviación, S.A.B. de C.V.
(Name of Registrant)
Av. Antonio Dovalí Jaime No. 70, 13 Floor, Tower B
Colonia Zedec Santa Fe, Alcaldía Álvaro Obregón
United Mexican States, Mexico City 01210
+(52) 55-5261-6400
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
EXPLANATORY NOTE
On April 17, 2026, Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS) issued a press release titled “Volaris amends its bylaws in accordance with the resolutions approved by the Extraordinary General Shareholders’ Meeting held on March 25, 2026.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1 and the courtesy English translation of the amended and restated bylaws is attached to this Form 6-K as Exhibit 99.2.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Controladora Vuela Compañía de Aviación, S.A.B. de C.V. |
||
| Date: April 17, 2026 | By: | /s/ Enrique J. Beltranena Mejicano |
Name: |
Enrique J. Beltranena Mejicano | |
Title: |
Chief Executive Officer | |
|
|
|
|
| By: | /s/ Jaime E. Pous Fernández | |
Name: |
Jaime E. Pous Fernández | |
Title: |
Chief Financial Officer | |
EXHIBIT INDEX
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
- The 6 Best Places to Get a Massage in Vancouver in 2026
- CZR Exchange Hosts Exclusive VIP Trading Community Experience During Monaco Grand Prix 2026
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share